Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Arcus Biosciences stock | 22.68

Own Arcus Biosciences stock in just a few minutes.


Fact checked

Arcus Biosciences, Inc is a biotechnology business based in the US. Arcus Biosciences shares (RCUS) are listed on the NYSE and all prices are listed in US Dollars. Arcus Biosciences employs 139 staff and has a trailing 12-month revenue of around USD$77.8 million.

How to buy shares in Arcus Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Arcus Biosciences. Find the stock by name or ticker symbol: RCUS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arcus Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$22.68, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arcus Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Arcus Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Arcus Biosciences's share price?

Since the stock market crash in March caused by coronavirus, Arcus Biosciences's share price has had significant positive movement.

Its last market close was USD$22.68, which is 23.63% up on its pre-crash value of USD$17.32 and 151.02% up on the lowest point reached during the March crash when the shares fell as low as USD$9.035.

If you had bought USD$1,000 worth of Arcus Biosciences shares at the start of February 2020, those shares would have been worth USD$1,138.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,459.87.

Arcus Biosciences share price

Use our graph to track the performance of RCUS stocks over time.

Arcus Biosciences shares at a glance

Information last updated 2020-11-27.
Latest market close USD$22.68
52-week range USD$7.69 - USD$37.41
50-day moving average USD$21.5729
200-day moving average USD$23.8558
Wall St. target price USD$37.78
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.589

Buy Arcus Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arcus Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcus Biosciences price performance over time

Historical closes compared with the close of $22.68 from 2020-11-16

1 week (2020-11-19) N/A
1 month (2020-10-30) 4.04%
3 months (2020-08-26) N/A
6 months (2020-05-26) N/A
1 year (2019-11-26) N/A
2 years (2018-11-26) N/A
3 years (2017-11-26) N/A
5 years (2015-11-26) N/A

Arcus Biosciences financials

Revenue TTM USD$77.8 million
Gross profit TTM USD$-63,481,000
Return on assets TTM -10.91%
Return on equity TTM -24.28%
Profit margin -112.63%
Book value $8.385
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting Arcus Biosciences shares

There are currently 6.6 million Arcus Biosciences shares held short by investors – that's known as Arcus Biosciences's "short interest". This figure is 5.3% down from 7.0 million last month.

There are a few different ways that this level of interest in shorting Arcus Biosciences shares can be evaluated.

Arcus Biosciences's "short interest ratio" (SIR)

Arcus Biosciences's "short interest ratio" (SIR) is the quantity of Arcus Biosciences shares currently shorted divided by the average quantity of Arcus Biosciences shares traded daily (recently around 599883.55916893). Arcus Biosciences's SIR currently stands at 11.07. In other words for every 100,000 Arcus Biosciences shares traded daily on the market, roughly 11070 shares are currently held short.

However Arcus Biosciences's short interest can also be evaluated against the total number of Arcus Biosciences shares, or, against the total number of tradable Arcus Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcus Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Arcus Biosciences shares in existence, roughly 100 shares are currently held short) or 0.1288% of the tradable shares (for every 100,000 tradable Arcus Biosciences shares, roughly 129 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arcus Biosciences.

Find out more about how you can short Arcus Biosciences stock.

Arcus Biosciences share dividends

We're not expecting Arcus Biosciences to pay a dividend over the next 12 months.

Arcus Biosciences share price volatility

Over the last 12 months, Arcus Biosciences's shares have ranged in value from as little as $7.69 up to $37.41. A popular way to gauge a stock's volatility is its "beta".

RCUS.US volatility(beta: 1.19)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Arcus Biosciences's is 1.1854. This would suggest that Arcus Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Arcus Biosciences overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. The company was founded in 2015 and is based in Hayward, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site